Skip to main content
. 2022 May 4;23(9):5105. doi: 10.3390/ijms23095105

Figure 4.

Figure 4

Acetylsalicylic acid is a PC-enhancer. IF-GLA-MUTs, specifically C56Y (A), L300F (B), D244H (C), V269M (D), and Q280K (E), were treated for 72 h with the following drugs: i. untreated; ii. 10 μM DGJ; iii. 4 mM acetylsalicylic acid (ASA); iv. 10 μM DGJ + 4 mM ASA. IF-NULL was used as a control (F). AGAL specific activity measured on protein extracts is shown. Tukey’s HSD was used to evaluate significative differences among treatments (***: p < 0.001; **: p < 0.01; *: p < 0.05; n = 2). The effects of combined treatment (DGJ + ASA) are significantly higher than those of DGJ monotherapy. Immunoblots confirmed the results (U = untreated; D = DGJ 10 μM; A = ASA 4 mM; D + A = DGJ 10 μM + ASA 4 mM). Each panel includes specific activity and an immunoblot for a cell line.